AbbVie bets up to $1.47B for Nxera’s discarded IBD program
AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.
AbbVie’s $100 million upfront cash payment will purchase global rights to Nxera’s deprioritized oral small molecule, which has already completed Phase 1 testing.
comments(0)
5-min edit window · permanent after that